{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:45:22Z","timestamp":1791067522873,"version":"4.1.0"},"reference-count":40,"publisher":"American Association for Cancer Research (AACR)","issue":"7","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypoxia inducible factors (HIF) are critical mediators of the cellular response to decreased oxygen tension and are overexpressed in a number of tumors. Although HIF1\u03b1 and HIF2\u03b1 share a high degree of sequence homology, recent work has shown that the two \u03b1 subunits can have contrasting and tissue-specific effects on tumor growth. To directly compare the role of each HIF\u03b1 subunit in spontaneous tumorigenesis, we bred a mouse model of expanded HIF2\u03b1 expression and Hif1\u03b1+\/\u2212 mice to homozygotes for the R270H mutation in p53. Here, we report that p53R270H\/R270H mice, which have not been previously described, develop a unique tumor spectrum relative to p53R270H\/\u2212 mice, including a high incidence of thymic lymphomas. Heterozygosity for Hif1\u03b1 significantly reduced the incidence of thymic lymphomas observed in this model. Moreover, reduced Hif1\u03b1 levels correlated with decreased stabilization of activated Notch1 and expression of the Notch target genes, Dtx1 and Nrarp. These observations uncover a novel role for HIF1\u03b1 in Notch pathway activation during T-cell lymphomagenesis. [Cancer Res 2009;69(7):3213\u201320]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-4223","type":"journal-article","created":{"date-parts":[[2009,3,17]],"date-time":"2009-03-17T22:13:29Z","timestamp":1237328009000},"page":"3213-3220","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Heterozygosity for\n                    <i>Hypoxia Inducible Factor 1\u03b1<\/i>\n                    Decreases the Incidence of Thymic Lymphomas in a p53 Mutant Mouse Model"],"prefix":"10.1158","volume":"69","author":[{"given":"Jessica A.","family":"Bertout","sequence":"first","affiliation":[{"name":"1Abramson Family Cancer Research Institute,"},{"name":"2School of Veterinary Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shetal A.","family":"Patel","sequence":"additional","affiliation":[{"name":"1Abramson Family Cancer Research Institute,"},{"name":"3School of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin H.","family":"Fryer","sequence":"additional","affiliation":[{"name":"1Abramson Family Cancer Research Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C.","family":"Durham","sequence":"additional","affiliation":[{"name":"2School of Veterinary Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Covello","sequence":"additional","affiliation":[{"name":"1Abramson Family Cancer Research Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth P.","family":"Olive","sequence":"additional","affiliation":[{"name":"1Abramson Family Cancer Research Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"2School of Veterinary Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Celeste","family":"Simon","sequence":"additional","affiliation":[{"name":"1Abramson Family Cancer Research Institute,"},{"name":"3School of Medicine,"},{"name":"4Howard Hughes Medical Institute, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2009,4,1]]},"reference":[{"key":"2022061701491073400_B1","doi-asserted-by":"crossref","unstructured":"Gordan JD, Simon MC. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev\u20082007; 17: 71\u20137.","DOI":"10.1016\/j.gde.2006.12.006"},{"key":"2022061701491073400_B2","doi-asserted-by":"crossref","unstructured":"Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE\u20082005; 2005: re12.","DOI":"10.1126\/stke.3062005re12"},{"key":"2022061701491073400_B3","doi-asserted-by":"crossref","unstructured":"Jain S, Maltepe E, Lu MM, Simon C, Bradfield CA. Expression of ARNT, ARNT2, HIF1 \u03b1, HIF2 \u03b1 and Ah receptor mRNAs in the developing mouse. Mech Dev\u20081998; 73: 117\u201323.","DOI":"10.1016\/S0925-4773(98)00038-0"},{"key":"2022061701491073400_B4","doi-asserted-by":"crossref","unstructured":"Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev\u20081997; 11: 72\u201382.","DOI":"10.1101\/gad.11.1.72"},{"key":"2022061701491073400_B5","doi-asserted-by":"crossref","unstructured":"Wiesener MS, Jurgensen JS, Rosenberger C, et al. Widespread hypoxia-inducible expression of HIF-2\u03b1 in distinct cell populations of different organs. FASEB J\u20082003; 17: 271\u20133.","DOI":"10.1096\/fj.02-0445fje"},{"key":"2022061701491073400_B6","doi-asserted-by":"crossref","unstructured":"Covello KL, Kehler J, Yu H, et al. HIF-2\u03b1 regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev\u20082006; 20: 557\u201370.","DOI":"10.1101\/gad.1399906"},{"key":"2022061701491073400_B7","doi-asserted-by":"crossref","unstructured":"Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC, Differential roles of hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1) and HIF-2\u03b1 in hypoxic gene regulation. Mol Cell Biol\u20082003; 23: 9361\u201374.","DOI":"10.1128\/MCB.23.24.9361-9374.2003"},{"key":"2022061701491073400_B8","doi-asserted-by":"crossref","unstructured":"Gruber M, Hu CJ, Johnson RS, et al. Acute postnatal ablation of Hif-2\u03b1 results in anemia. Proc Natl Acad Sci U S A\u20082007; 104: 2301\u20136.","DOI":"10.1073\/pnas.0608382104"},{"key":"2022061701491073400_B9","unstructured":"Ryan HE, Poloni M, McNulty W, et al. Hypoxia-inducible factor-1\u03b1 is a positive factor in solid tumor growth. Cancer Res\u20082000; 60: 4010\u20135."},{"key":"2022061701491073400_B10","doi-asserted-by":"crossref","unstructured":"Holmquist-Mengelbier L, Fredlund E, Lofstedt T, et al. Recruitment of HIF-1\u03b1 and HIF-2\u03b1 to common target genes is differentially regulated in neuroblastoma: HIF-2\u03b1 promotes an aggressive phenotype. Cancer Cell\u20082006; 10: 413\u201323.","DOI":"10.1016\/j.ccr.2006.08.026"},{"key":"2022061701491073400_B11","doi-asserted-by":"crossref","unstructured":"Kondo K, Kim WY, Lechpammer M, Kaelin WG, Jr. Inhibition of HIF2\u03b1 is sufficient to suppress pVHL-defective tumor growth. PLoS Biol\u20082003; 1: E83.","DOI":"10.1371\/journal.pbio.0000083"},{"key":"2022061701491073400_B12","doi-asserted-by":"crossref","unstructured":"Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG, Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell\u20082002; 1: 237\u201346.","DOI":"10.1016\/S1535-6108(02)00043-0"},{"key":"2022061701491073400_B13","doi-asserted-by":"crossref","unstructured":"Maranchie JK, Vasselli JR, Riss J, et al. The contribution of VHL substrate binding and HIF1-\u03b1 to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell\u20082002; 1: 247\u201355.","DOI":"10.1016\/S1535-6108(02)00044-2"},{"key":"2022061701491073400_B14","doi-asserted-by":"crossref","unstructured":"Raval RR, Lau KW, Tran MG, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol\u20082005; 25: 5675\u201386.","DOI":"10.1128\/MCB.25.13.5675-5686.2005"},{"key":"2022061701491073400_B15","doi-asserted-by":"crossref","unstructured":"Acker T, Diez-Juan A, Aragones J, et al. Genetic evidence for a tumor suppressor role of HIF-2\u03b1. Cancer Cell\u20082005; 8: 131\u201341.","DOI":"10.1016\/j.ccr.2005.07.003"},{"key":"2022061701491073400_B16","doi-asserted-by":"crossref","unstructured":"Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor-1\u03b1 is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res\u20082007; 67: 563\u201372.","DOI":"10.1158\/0008-5472.CAN-06-2701"},{"key":"2022061701491073400_B17","doi-asserted-by":"crossref","unstructured":"Covello KL, Simon MC, Keith B. Targeted replacement of hypoxia-inducible factor-1\u03b1 by a hypoxia-inducible factor-2\u03b1 knock-in allele promotes tumor growth. Cancer Res\u20082005; 65: 2277\u201386.","DOI":"10.1158\/0008-5472.CAN-04-3246"},{"key":"2022061701491073400_B18","doi-asserted-by":"crossref","unstructured":"Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia-inducible factors HIF-1\u03b1 and HIF-2\u03b1 in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol\u20082000; 157: 411\u201321.","DOI":"10.1016\/S0002-9440(10)64554-3"},{"key":"2022061701491073400_B19","doi-asserted-by":"crossref","unstructured":"Olive KP, Tuveson DA, Ruhe ZC, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell\u20082004; 119: 847\u201360.","DOI":"10.1016\/j.cell.2004.11.004"},{"key":"2022061701491073400_B20","doi-asserted-by":"crossref","unstructured":"Wijnhoven SW, Speksnijder EN, Liu X, et al. Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. Cancer Res\u20082007; 67: 4648\u201356.","DOI":"10.1158\/0008-5472.CAN-06-4681"},{"key":"2022061701491073400_B21","doi-asserted-by":"crossref","unstructured":"Wijnhoven SW, Zwart E, Speksnijder EN, et al. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res\u20082005; 65: 8166\u201373.","DOI":"10.1158\/0008-5472.CAN-05-1650"},{"key":"2022061701491073400_B22","doi-asserted-by":"crossref","unstructured":"Jackson EL, Olive KP, Tuveson DA, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res\u20082005; 65: 10280\u20138.","DOI":"10.1158\/0008-5472.CAN-05-2193"},{"key":"2022061701491073400_B23","unstructured":"Nacht M, Jacks T. V(D)J recombination is not required for the development of lymphoma in p53-deficient mice. Cell Growth Differ\u20081998; 9: 131\u20138."},{"key":"2022061701491073400_B24","doi-asserted-by":"crossref","unstructured":"Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2\u03b1 promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell\u20082007; 11: 335\u201347.","DOI":"10.1016\/j.ccr.2007.02.006"},{"key":"2022061701491073400_B25","doi-asserted-by":"crossref","unstructured":"O'Neil J, Calvo J, McKenna K, et al. Activating Notch1 mutations in mouse models of T-ALL. Blood\u20082006; 107: 781\u20135.","DOI":"10.1182\/blood-2005-06-2553"},{"key":"2022061701491073400_B26","doi-asserted-by":"crossref","unstructured":"Attardi LD, Jacks T. The role of p53 in tumour suppression: lessons from mouse models. Cell Mol Life Sci\u20081999; 55: 48\u201363.","DOI":"10.1007\/s000180050269"},{"key":"2022061701491073400_B27","doi-asserted-by":"crossref","unstructured":"Aster JC, Pear WS, Blacklow SC. Notch signaling in leukemia. Annu Rev Pathol\u20082008; 3: 587\u2013613.","DOI":"10.1146\/annurev.pathmechdis.3.121806.154300"},{"key":"2022061701491073400_B28","doi-asserted-by":"crossref","unstructured":"Sjolund J, Manetopoulos C, Stockhausen MT, Axelson H. The Notch pathway in cancer: differentiation gone awry. Eur J Cancer\u20082005; 41: 2620\u20139.","DOI":"10.1016\/j.ejca.2005.06.025"},{"key":"2022061701491073400_B29","doi-asserted-by":"crossref","unstructured":"Gustafsson MV, Zheng X, Pereira T, et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell\u20082005; 9: 617\u201328.","DOI":"10.1016\/j.devcel.2005.09.010"},{"key":"2022061701491073400_B30","doi-asserted-by":"crossref","unstructured":"Terzian T, Suh YA, Iwakuma T, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev\u20082008; 22: 1337\u201344.","DOI":"10.1101\/gad.1662908"},{"key":"2022061701491073400_B31","doi-asserted-by":"crossref","unstructured":"Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol\u20082007; 9: 573\u201380.","DOI":"10.1038\/ncb1571"},{"key":"2022061701491073400_B32","doi-asserted-by":"crossref","unstructured":"Bassing CH, Suh H, Ferguson DO, et al. Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell\u20082003; 114: 359\u201370.","DOI":"10.1016\/S0092-8674(03)00566-X"},{"key":"2022061701491073400_B33","doi-asserted-by":"crossref","unstructured":"Ward IM, Difilippantonio S, Minn K, et al. 53BP1 cooperates with p53 and functions as a haploinsufficient tumor suppressor in mice. Mol Cell Biol\u20082005; 25: 10079\u201386.","DOI":"10.1128\/MCB.25.22.10079-10086.2005"},{"key":"2022061701491073400_B34","doi-asserted-by":"crossref","unstructured":"Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer\u20082008; 8: 51\u20136.","DOI":"10.1038\/nrc2274"},{"key":"2022061701491073400_B35","doi-asserted-by":"crossref","unstructured":"Gao P, Zhang H, Dinavahi R, et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell\u20082007; 12: 230\u20138.","DOI":"10.1016\/j.ccr.2007.08.004"},{"key":"2022061701491073400_B36","doi-asserted-by":"crossref","unstructured":"Pear WS, Aster JC, Scott ML, et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med\u20081996; 183: 2283\u201391.","DOI":"10.1084\/jem.183.5.2283"},{"key":"2022061701491073400_B37","doi-asserted-by":"crossref","unstructured":"Aster JC, Xu L, Karnell FG, et al. Essential roles for ankyrin repeat and transactivation domains in induction of T-cell leukemia by notch1. Mol Cell Biol\u20082000; 20: 7505\u201315.","DOI":"10.1128\/MCB.20.20.7505-7515.2000"},{"key":"2022061701491073400_B38","doi-asserted-by":"crossref","unstructured":"Bellavia D, Campese AF, Alesse E, et al. Constitutive activation of NF-\u03baB and T-cell leukemia\/lymphoma in Notch3 transgenic mice. EMBO J\u20082000; 19: 3337\u201348.","DOI":"10.1093\/emboj\/19.13.3337"},{"key":"2022061701491073400_B39","doi-asserted-by":"crossref","unstructured":"Sharma VM, Calvo JA, Draheim KM, et al. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol\u20082006; 26: 8022\u201331.","DOI":"10.1128\/MCB.01091-06"},{"key":"2022061701491073400_B40","doi-asserted-by":"crossref","unstructured":"Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science\u20082004; 306: 269\u201371.","DOI":"10.1126\/science.1102160"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/7\/3213\/2624146\/3213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/7\/3213\/2624146\/3213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T05:23:36Z","timestamp":1655443416000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/69\/7\/3213\/553359\/Heterozygosity-for-Hypoxia-Inducible-Factor-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,1]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2009,4,1]]},"published-print":{"date-parts":[[2009,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-4223","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22381205","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381199.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381196.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381208","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381208.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381202.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6499787","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381190","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381205.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6499787.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381190.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381193.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381193","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381196","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381202","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381199","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,1]]}}}